US 12,268,664 B1
Administration of benzodiazepine compositions
Steve Cartt, Hillsborough, CA (US); David Medeiros, Sparks, NV (US); Garry Thomas Gwozdz, Jim Thorpe, PA (US); Andrew Loxley, Brussels (BE); Mark Mitchnick, East Hampton, NY (US); David F. Hale, San Diego, CA (US); and Edward T. Maggio, San Diego, CA (US)
Assigned to Neurelis, Inc., San Diego, CA (US)
Filed by Neurelis, Inc., San Diego, CA (US)
Filed on Jul. 24, 2024, as Appl. No. 18/782,666.
Application 18/782,666 is a continuation of application No. 18/062,062, filed on Dec. 6, 2022.
Application 18/062,062 is a continuation of application No. 17/228,514, filed on Apr. 12, 2021, granted, now 11,793,786, issued on Oct. 24, 2023.
Application 17/228,514 is a continuation of application No. 15/955,397, filed on Apr. 17, 2018, abandoned.
Application 15/955,397 is a continuation of application No. 12/413,439, filed on Mar. 27, 2009, abandoned.
Claims priority of provisional application 61/040,558, filed on Mar. 28, 2008.
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/355 (2006.01); A61K 9/00 (2006.01); A61K 31/5513 (2006.01)
CPC A61K 31/355 (2013.01) [A61K 9/0043 (2013.01); A61K 9/008 (2013.01); A61K 31/5513 (2013.01)] 18 Claims
 
1. A pharmaceutical composition for intranasal administration comprising:
about 1 to about 20 mg of diazepam dissolved in about 45% to about 85% (w/w) of one or more natural or synthetic tocopherols or tocotrienols selected from the group consisting of: α-tocopherol, β-tocopherol, γ-tocopherol, δ-tocopherol, α-tocotrienol, β-tocotrienol, γ-tocotrienol, δ-tocotrienol, tocophersolan, any esters thereof and any combinations thereof, and about 25% to about 40% (w/w) of one or more alcohols selected from the group consisting of ethanol, propyl alcohol, butyl alcohol, pentanol, benzyl alcohol, and any combinations thereof, and about 0.01% to about 1% (w/v) of dodecyl β-D-maltoside, wherein the pharmaceutical composition is a solution and contains less than 1% water, wherein the pharmaceutical composition is in a pharmaceutically-acceptable spray formulation.